Both the firms have not disclosed financial details of the deal, under which Eurolab has agreed to specific annual commercial goals for Brinavess.
Cardiome chief commercial officer Karim Lalji said the deal with Eurolab allows for the continued availability of Brinavess to the company’s customers in Argentina.
"As the third largest country in South America in terms of population, Argentina remains a key market for Brinavess as we continue to build the brand in this region," Lalji said.
Cardiome develops and commercializes cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease.
Brinavess (vernakalant IV) and AGGRASTAT (tirofiban HCl) a reversible GP IIb/IIIa inhibitor are Cardiome’s two marketed, in-hospital, cardiology products.
In Europe and other territories, Brinavess is approved for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults, while AGGRASTAT is indicated for use in patients with acute coronary syndrome.
Eurolab general manager Gabriel Menendez said the company is happy to expand its hospital product offerings to its customers with the addition of Brinavess to its portfolio.
"We are committed to making this important drug for the conversion of atrial fibrillation available to all of our customers throughout the country," Menendez said.
Eurolab, which produces its own prescription and OTC products, supports the Multinational Pharmaceutical Industry in the areas of manufacturing, promotion and distribution of medicines in Argentina and Latin America.